Therapeutic Effects of Anti-PD1 Immunotherapy on Hepatocellular Carcinoma Under Administration of Tacrolimus
Journal
Transplantation
Journal Volume
107
Journal Issue
7
Pages
1492 - 1501
Date Issued
2023-07-01
Author(s)
Hsu, Yu-Chen
Lee, Ying-Te
Wu, Meng-Chuan
Su, Chien-Wen
Chou, Huei-Chi
Wang, Li-Fang
Sheu, Jin-Chuan
Abstract
Liver transplantation (LT) is the treatment of choice for patients with hepatocellular carcinoma (HCC). Recurrence of HCC after LT occurs in 10% to 20% of cases. Preclinical studies to evaluate immune checkpoint inhibitors in conjunction with immunosuppressant treatment in transplant recipients have been lacking. Here, we evaluated the efficacy, safety, and mechanism of programmed cell death-1 (PD1) blockade under tacrolimus treatment in transplant recipients.
Type
journal article